Cardiff Oncology, Inc.
CRDF
$2.41
-$0.03-1.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 11.01% | -27.81% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.01% | -27.81% | |||
| Cost of Revenue | 10.53% | 7.88% | |||
| Gross Profit | -10.52% | -8.44% | |||
| SG&A Expenses | -17.34% | 33.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.81% | 13.90% | |||
| Operating Income | -2.75% | -14.40% | |||
| Income Before Tax | -3.79% | -13.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.79% | -13.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.79% | -13.97% | |||
| EBIT | -2.75% | -14.40% | |||
| EBITDA | -2.76% | -14.53% | |||
| EPS Basic | -3.81% | 7.13% | |||
| Normalized Basic EPS | -3.80% | 7.14% | |||
| EPS Diluted | -3.81% | 7.13% | |||
| Normalized Diluted EPS | -3.80% | 7.14% | |||
| Average Basic Shares Outstanding | 0.00% | 22.70% | |||
| Average Diluted Shares Outstanding | 0.00% | 22.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||